Samsung Biologics Nears Completion of 2.7 Trillion Won Paid-in Capital Increase… Subscription Rate 96.8%

조선일보

Lean Right

Factuality

Ownership

Samsung Biologics recorded a subscription rate of 96.8% in a 2.665 trillion won paid-in capital increase pursued to raise funds for the acquisition of Switzerland's Polypeptide Group. With major shareholders, including Samsung C&T and Samsung Electronics, subscribing for their entire allocated shares, the large-scale fundraising process has entered its final stages. During the subscription for the paid-in capital increase conducted on the 9th an…

ddaily.co.kr

Factuality

Ownership

[Digital Daily Reporter Wang Jin-hwa] Samsung Biologics recorded a subscription rate of 96.8% in a paid-in capital increase worth approximately 2.7 trillion won. The financing process for the acquisition of Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO), has entered its final stage. Samsung Biologics announced on the 11th that a total of 2,198,146 shares were subscribed during the paid-in capital …